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The aims of this study were to obtain a circular map of a pLG1 replicon type plasmid in 
E. faecium (TUH 56-32), derived from the trans-conjugation between E. faecium (K60-
39), donor and (BM4105-RF) recipient strains and also to detect the presence of and 
describe the prevalence of selected open reading frames (ORF) from a clinical and non-
clinical collection of E. faecium and E. faecalis strains.      
  
The DNA sequence of E. faecium (TUH56-32)  plasmid was subjected to gaps closure. 
Gaps closure was performed by PCR to obtain a circular map of the plasmid sequence. 
To detect the presence of ORFs total DNA was extracted from a clinical and non-clinical 
collection of 150 isolates which consisted of 116 E. faecium and 34 E. faecalis. PCR was 
applied to detect the presence of ORFs. 
 
The gaps closing experiment was not accomplished and therefore did not give a circular 
DNA. However, the screening experiment was completed and the detection and 
description of ORFs among E. faecium showed that isolates from blood cultures 
harboured more ORFs than those of other clinical and non-clinical sources.  Those of 
non-clinical cultures however lacked three of the tested ORFs. The prevalence was 
higher among clinical isolates of all sources compared to non-clinical isolates.  Isolates 
of E. faecium detected more prevalently to all ORFs than E. faecalis. The isolates derived 
from blood cultures were highly enriched with all four ORFs compared to isolates from 
other clinical sources. Blood culture isolates harbouring all ORFs differed significantly 
to those of other clinical sources. In summary, the tested ORFs were overrepresented in 
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Because of their ability to cause public health hazards, enterococci are gaining more 
attention in recent years.  Growing incidence of hospital associated enterococci has 
emerged, with E. faecium being in the lead (Felmingham et al., 1992). They are involved 
in antimicrobial resistance and hospital acquired infections (JUREEN, R. 2004). 
Enterococci belong to the genus enterococcus and were previously composed of 19 
species (Monstein et al., 1998). In recent years the number of species has grown 
significantly as new methods are being implimented (Carvalho Mda et al., 2004, Law-
Brown and Meyers, 2003). 
 
General characteristics  
 
The Enterococci are Gran positive bacteria, facultative anaerobic, catalysed  negative, 
occur in pairs, but can also be seen in short chains (Deibel et al., 1963). They are 
naturally found in the gastrointestinal tract of mammals and are capable of surviving in 
harsh environments (Arias and Murray, 2012). They are capable of growing in harsh 
environments such as broth containing high sodium chloride concentration (6, 5%) and 
broad range pH (4- 9, 6).  Growth also occur at 10 0C and 45 0 C (Deibel et al., 1963). 
They can also be stored at – 70oC for a long period of time (K-res,UiT).  
 
E. faecium and E. faecalis 
 
The genus enterococcus consists of several species including E. faecium and E. faecalis, 
which are among the clinically important species causing nosocomial infections in the 
human population. They are said to have acquired distinctive features allowing them to 
colonize the human host often causing infection (Vankerckhoven et al., 2004, Seno et al., 
2005). Infections of the urinary tract of humans are common examples (Felmingham et 
al., 1992). Because of genetic diversity, they are regarded as two distinct species. 




faecium than E. faecalis and larger in E. faecium than in E. faecalis. Another difference 
also highlights the presence of larger plasmids that have been detected in E. faecium  
known as the pLG1 replicon type that are not found in E. faecalis (Rosvoll et al., 2012) . E. 
faecalis however are shown to harbour pheromone responsive plasmids which are not 
found in E. faecium (Lim et al., 2006). These species are both described of hosting an 
open pan-genome, which means they are capable of acquiring and integrating foreign 
genetic elements into their genome (Tettelin et al., 2008).  E. faecalis and E. faecium are 
the leading cause of hospital acquired infections within their genus, with previous 
accounts showing 90-95% of cases caused by E. faecalis and 5-10% of cases caused by E. 
faecium (Arias and Murray, 2012). Recent accounts however, showed that E. faecium has 
taken the lead. In 2002, an American study which lasted over a decade showed a 10% 
increase in clinical isolates within E. faecium, while E. faecalis were stable throughout 
the 10 year  period (Treitman et al., 2005).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
 
Hospital and community associated lineages 
 
Enterococci can be grouped into hospital associated and community associated clades. 
They have been discussed in many studies and are said to differ significantly in their 
genetic property(Kim and Marco, 2013, Brodal, 2011). Furthermore, isolates associated 
with hospital environments have been grouped into clonal complexes and their 
subpopulations to differ them from non-clinical isolates, with most common clonal 
complexes being CC17, E. faecium and CC2 E. faecalis (Valdezate et al., 2012, Rosvoll et 
al., 2012, Freitas et al., 2009). It has also being shown that the two groups are 
genetically far apart, which could explain their choice to populate different niches(Kim 
and Marco, 2013, Brodal, 2011). Distinguishing those that are disease causing 
pathogens from those that do not cause disease is important in identifying strains that 
are high-risk pathogens and those with the potentials to transform from low-risk into 
high-risk pathogens (de Regt et al., 2012). In the study complete genome sequence of 
the E. faecium strain TX16, Qin et al. (2012) highlighted a significant difference between 
clinical and non-clinical clades with 3-4% averaged nucleotide sequence difference 






Mobile genetic elements (MGEs) of enterococci 
 
The MEGs of Enterococci include plasmids, complex transposons, integrative 
conjugative plasmids and insertion sequence elements. Recent studies showed that 
enterococci are capable of absorbing and incorporating foreign elements into their 
genome as a means of adapting to various environmental pressures (Angulo et al., 2006, 
Macovei and Zurek, 2007,). However the transfer of mobile genetic elements across 
genetic lines is an important process and seems to enforce adaptability and persistence 
in various niches (Santagati et al., 2012).  MEGs are by definition simple fragments of 
DNA consisting of different sizes and genetic properties that are capable of free 
movement between genomes or within genomes (Santagati et al., 2012). First 
discovered in the late 1940s, a lot has been understood in terms of how they function, 
thanks to decade long genome sequence studies.  Moreover, they can be crucial in part 
due to their diverse nature. Studies showed that the acquisition of MEGs could impose 
unfavourable conditions to the species which they are hosted by leading to fitness 
problems (Starikova et al., 2013). On the other hand, some encode genes that confer 
resistance to antibiotics, while others provide key determinants for virulence (Paulsen 
et al., 2003). Interspecies variation in content of MGEs can also exist among clinical E. 
faecium and non-clinical E. faecium. For example previous accounts showed that clinical 
E. faecium are more enriched in MGEs than non-clinical E. faecium strains (Kim and 
Marco, 2013). These differences might also correlate with the fact that there are 
considerable distances between the two clades on the genome level. Previous accounts 
also showed that non-clinical E. faecium contain smaller genome compared to clinical E. 









Plasmids are described as circular DNA molecules capable of replicating independently 
of the bacterial chromosome. In enterococci plasmids form an integral part of the cell 
enabling survival and adaptation in new niches. Genetic studies of enterococci showed 
different plasmids types, and that plasmids differ greatly in size which also reflects their 
genetic content (Jensen et al., 2010). Based on their transfer mechanism three main 
groups of plasmids have been described in enterococci which includes conjugative 
plasmids, non-conjugative plasmids and pheromone responsive conjugative plasmid 
(Paulsen et al., 2003). Enterococcal plasmids can be broad host range or narrow host 
range. Broad host range plasmids exist in more than one species, while narrow host 
range plasmids are species specific. Example of arrow host range plasmids include 
pheromone responsive plasmids which are predominantly enriched among E. faecalis 
populations (Clewell, 2011).  
 
 
Horizontal gene transfer 
 
Horizontal gene transfer highlights the genetic exchange among bacteria and can be 
described in three ways: 1. Conjugation 2.Transduction 3.Transformation. Since 
transduction and transformation have not yet been identified in enterococci only 
conjugation will be discussed here. Bacterial conjugation involves the exchange of 
genetic elements as a mean of acquiring or spreading antimicrobial resistance genes or 
virulence factors by direct cell to cell contact (Goessweiner-Mohr et al., 2012), Model of 
this transfer has been proposed previously in gram-positive bacteria (Abajy et al., 
2007). Conjugation provides the basics upon which MGEs such as plasmids and other 
transposons are exchanged and spread among enterococci (Rosvoll et al., 2012). The 
mechanism of conjugation involves the recruitment of so called tra-proteins to the type 
IV secretion-like system (T4SS-like complex) (Abajy et al., 2007).  However the T4SS-
like system of enterococci have been identified previously and are said to be quite 
similar to the T4SS system of other gram-positive bacteria (Goessweiner-Mohr et al., 






Pheromone responsive plasmids and transfer mechanism 
 
Enterococcal pheromone responsive plasmid conjugation is based upon the presence of 
a special protein called sex-pheromones (An and Clewell, 2002). Sex pheromones are, 
upon their release found on the outside of the cell and are specific for donors conveying 
conjugative plasmids. These signal proteins are released by the recipient cell and are 
chromosomally encoded (Palmer et al., 2010). In the presence of sex pheromones 
donors are triggered to response due to their pheromone sensitivity. In response they 
produce surface proteins called aggregation substances (ASs) (Kreft et al., 1992). ASs 
are responsible for linking the two cells into close proximity by binding to proteins 
called Enterococcal Binding Substances (EBS) that are present at the surface of the 
recipient cell. This triggers a conformational change which enables the exchange 
process to take place.  Once the transfer is complete the recipient cell then ceases the 
production of sex pheromone (Clewell, 2011). The mating process shuts down once that 
plasmid is transferred, but does not hinder the continuing transfer of other plasmid 
types as pheromones are plasmid specific.  However, acting donor cells produce plasmid 
encoded inhibitors that inhibit aggregation substances preventing further aggregation 
and hence the transfer of yet the same plasmid type (Clewell, 2011).  
 
 
Megaplasmids of enterococci 
 
Megaplasmid is an old phenomenon that was used to describe bacteria plasmids of very 
large sizes. The use of this phenomenon to described bacteria plasmids was first 
invented in 1981 by Rosenberg and co-workers (Rosenberg et al., 1981). Megaplasmids 
are also extra chromosomal genetic materials that are capable of self-replicating and 
therefor do not replicate dependent of the cell chromosomes  (Steinbüchel and 
Schwartz, 2009). No threshold has been adapted for megaplasmids as regards to size; 
and so the threshold could vary from study to study depending on the kind of species 
that are studied. Most studies including E. faecium consider megaplasmid to be above 




2010). Laverde Gomez et al. (2011) showed that megaplasmid of E. faecium can range 
from 150 kb to 350 kb. They are said to encode genetic elements with virulence and 
resistance potentials (Laverde Gomez et al., 2011, Rice et al., 2003) . In their research, 
Garcia-Migura et al. (2011) showed an E. faecium strain that harboured 70 kb plasmid 
before it was subjected to trans-conjugation. The result was a 120-140 kb size plasmid 
after the experiment was conducted, suggesting the possibility of genetic recombination 
of plasmids (Willems and van Schaik, 2009, Willems et al., 2001).  
 
 
Toxin – Antitoxin systems of enterococci 
 
The toxin-antitoxin system is vital in maintenance of virulence factors, antimicrobial 
resistance genes and other mobile genetic elements (Grady and Hayes, 2003). It plays 
an important role in the management of cell growth and prevents premature cell death 
(Grady and Hayes, 2003). Toxin-antitoxin systems have previously been identified 
among enterococci. They can be described as a system containing toxins that are 
neutralized by antitoxins (Grady and Hayes, 2003). However, genes that express toxin 
and antitoxin are regulated by the transcription of regulators of the TA operon (Boss et 
al., 2013). Without antitoxins the effect of toxins on mobile genetic materials would 
make them unstable leading to maintenance problems (Boss et al., 2013). Four TA 
systems are previously identified in enterococci including axe-txe, mazEF, relB and ω-ε-
ζ toxin-antitoxin systems and have been detected on megaplasmids (Rosvoll, 2012). 
Initially discovered in enterococci was the axe-txe gene (Grady and Hayes, 2003). The 
toxin-antitoxin pair (axe-txe) is encoded by the axe-txe operon (Halvorsen et al., 2011a). 
The txe toxin is known to inhibit the growth of E. coli cells, but this effect can be highly 
compromised by the presence of axe antitoxin (Halvorsen et al., 2011b). The Txe toxin 
inhibits protein synthesis and causes cell death because proteins are the backbone of 
virtually all cells. The mechanism that inhibits protein synthesis involved the cleavage 
of an mRNA at the first base just next to the start codon (Halvorsen et al., 2011a). Since 
antitoxins are co-inhibitors of toxin`s activity in the cell, they could be potential drug 




detected and are said to induce plasmid stabilization in enterococci (Sletvold et al., 
2008, Moritz and Hergenrother, 2007, Grady and Hayes, 2003). 
 
 
Transposons of enterococci 
 
Transposons are transposable elements that are capable of transferring within genomes 
or between them (Roberts et al., 2008). Transposons are found in all species including 
humans and are thought to have a variety of functions (Huang et al., 2012). They are 
abundantly present in enterococci and are said to involve in the dissemination of 
virulence and resistance factors (Rosvoll et al., 2012).  In enterococci they include 
insertion sequence elements (ISE), Tn3-like transposons, composite transposons and 






Virulence factors of enterococci 
 
Enterococci were initially recognised as commensals of the human gut flora but are 
causing serious nosocomial infections in humans. This is in large part due to the 
emergence of virulent strains. Similar to resistance transfer in enterococci, virulence 
factors can also be transferred through the exchange of genetic elements (Arias et al., 
2009). The virulence of every pathogen is its ability to cause disease. Enterococcal 
virulence can be described in terms of  (1)   adhering to host tissues (2) invading and 
forming of abscesses (3) impairment of host inflammatory and immune responses and 
(3) secretion of  toxic materials to enhance biofilm formation.  (Salah et al., 2008). 
Previous study showed a relationship between the accumulation of virulence factors 
and biofilms formation (the process that leads to disease formation such as urinary 
tract infection (UTI) and sepsis) (Seno et al.,2005).  As indicated by Seno et al. (2005) E. 






Table 1: The most common virulence factors of Enterococci 
Factors Found in 
species: 
                                        Function Referance 
Esp E. faecium Involved in biofilm formation (Heikens et al., 2007) 
AS E.faecalis Adhesion to soft tissues (Chow et al., 1993) 
Hyl(efm) E.faecium Involved in glycoside hydrolyses (Arias et al., 2009) 
GelE  Hydrolyses gelatine (Duprè et al., 2003) 
Cytolysin E. faecalis, 
E. faecium 
Lyses erythrocytes (Chow et al., 1993) 
 
Known virulence genes of enterococci are listed in Table 1 and factors encoded by these 
genes are said to play an important role in the pathogenesis of E. faecium and E. faecalis. 
However, enterococci also differ in terms of virulence factors. For example, while E. 
faecalis harbours aggregation substances (AS), they are entirely absent in E. faecium 
(Hällgren et al. (2009).  Aggregations substances are said to be involved in pheromone 
inducible transfer of plasmids among E .faecalis and do not play any role in transfer of 
plasmids within E. faecium.  This is because E. faecium do not produce sex-pheromones 
and hence, aggregation substances. The study of potential virulence factors could 
highlight the prospects of future disease management. Knowledge of enterococcus 
pathogenesis is therefore important as it would lead to the discovery of new target sites 





















HYPOTHESIS AND AIMS 
 
 
The hypothesis of this study was that invasive E. faecium and E. faecalis encode 
virulence factors with immune invasive and host colonization properties which are 
secreted into the bloodstream during infection and that those genes encoding such 
factors are carried by transferable megaplasmids and are therefore more prevalent 
among isolates of blood cultures than those derived from other sources. 
 
The Primary aims were: 
 
 to obtain a circular map of a pLG1 replicon type plasmid from a blood culture 
isolate of E. faecium (K60-39), transconjugant (TUH56-32). 
 to detect the presence of and describe the prevalence of selected open reading 
frames (ORFs) encoded by megaplasmids in a clinical and non-clinical collection 
of E. faecium and E. faecalis strains. 
 
The future aims were to study and identify genetic factors that play an important role 

















Available contigs and further scaffold formation 
 
Before starting to gap close the K60-39/3D megaplasmid, it had already been DNA 
sequenced and assembled into what was known as contigs. Contigs are contiguous 
length of sequences of which the order of bases is known. Gaps are formed where two 
overlapping contigs end. The process involving contigs formation was done and 
Illumina DNA sequencing technology and mate pair libraries were applied. The method 
was not applied in this thesis and would therefore not be discussed. The main aim of 
this technique can be seen in figure I, which is to obtain what contiguous sequences 
based on overlapping fragment. Once the material was available for gaps closure, all 
that needed to be done was based on DNA amplification by a thermal cycler, detection 
of the amplified DNA on an agarose gel, sequencing of the amplified DNA and using PCR 
fragments in gaps closure. Different bioinformatics software tools were also needed for 




Strain collection:  
 
The total of 151 isolates was collected including 116 E.facium and 34 E.faecalis. Isolates 
were grouped according to source as shown in table 2. In addition transconjugant TUH 
56-32 originating from conjugation between donor K60-39 and recipient BM4105-RF 
was included and was also used in the gap closing project.  It was provided to by the 
Reference Centre for Detection of Antimicrobial Resistance (K-res). Moreover strains 
were collected in twelve different countries including Norway, Poland, Germany, The 
UK, Portugal, Australia, The United States, Spain, The Nederland, Denmark, Italy and 
Sweden. The most recent collection happened in 2013 in Norway and the United States. 
The first collection however took place in the United States in 1981. This means that 






Figure I: Schematic diagram of a scaffold. Contiguous sequences formed contig 1 and 
contig 2. Between to contiguous sequences are gaps with known length but unknown 













Table 2: The distribution of E.faecium and E.faecalis strains that were used in this study 
Source                                                                   E. faecium                    E. faecalis 
Human blood                                                             71                                    27 
 
 
Other-clinical isolates                                                30                                    7 
 
Non-clinical isolates                                                  15                                   0 
Total                                                                          116                                  34 
 
 
Reference strains:  
 
The reference strains that were used in this study were provided by the Reference 
Centre for the Detection of Antimicrobial Resistance and included two E. faecium 
strains. One was used as a negative control (TUH 18-06) and the other as a positive 
control (TUH-56-32). The positive control strain (TUH 56-32) resulted from conjugation 
between E. faecium (K60-39) donor strain and E. faecium (BM4105-RF) recipient strain 
and harboured the 3D megaplasmid. Both strains were used as controls for the 
screening of genes encoding potential virulence factors in the strain collection. Total 






















General bacteria growth condition:  
 
Samples were taken from deep storage at -70 o C (K-res) and were placed on ice before 
being transferred on blood agar plates using an inoculation loop. The transfer involved 
the spreading of small samples on the blood agar plate with an inoculation loop 
followed by streaking evenly across the entire plate. Once the samples were transferred 
onto the plates, they were incubated at 370 C for 20 hours. After overnight growth on 
blood agars, the plates were observed for growth and visual colonies were harvested by 
using a clean inoculation loop. The colonies were suspended into 2,5 mL of Brain Heart 
Infusion Broth (BHIB) and incubated at 37 o C for another 20 hours. The overnight 
growth mediums were shortly centrifuged at 8000 x g (8000rpm) for 10 min followed 
by discarding the supernatant.  The pelleted bacteria cells were further used for DNA 
extraction. The extraction involved the use of three different extraction kits according to 
product manufacturer description.  
 
Total DNA extraction: 
 
Total DNA was extracted from all the strains. The types of extraction Kits that were used 
included High performance plasmid Midi Kit (Omega, USA), E.Z.N.A Bacterial DNA Kit 
(Omega, USA) and Qiagen DNA Mini Kit (Qiagen, Germany). The High Performance 
Plasmid Midi Kit (Hp plasmid Midi Kit, Omega USA) was exclusively used to extract DNA 
from the trans-conjugant strain used in gap closure and was selected because it has 
been used to yield clean and quality DNA templates previously. Moreover, total DNA 
was extracted because it was assumed that most of the strains contained larger 
plasmids that could not separate from the bacteria chromosomal DNA. The principles 
for total DNA extraction involved pelleting of overnight cell cultures, lysing of the cell 
pellet, removal of bacteria proteins and ribonucleic acids (RNA), further washing the 
DNA template for removal of reagents and final capturing of DNA in a microcentrifuge 





DNA extraction using High Performance plasmid Midi Kit 
 
 To start with 30 mL of overnight cell cultures were transferred in 15 mL falcon 
tubes and centrifuged at 4000 x g for 10 min and the bacteria pellets were re 
suspended by vortexing in 2,25 mL of solution I(RNase A) after removal of the 
supernatant. 
 To the suspension 2, 25 mL of solution II and 5 mL of OB protease were added 
followed by inverting in 7 s and incubation at 5 min. 
            3, 2 mL of solution III were so added to the suspension and inverted 10 times  
 It was centrifuged at 12000 x g for 10 minutes at 4 0C to separate the pellet from 
the supernatant and the supernatant was used further. 
 A volume of 1 mL of equilibration buffer was pipetted into a HiBand® DNA Midi 
column that was pre-inserted into a 50 mL collection tube. It was set to 
equilibrate in 5 min followed by centrifugation at 3000 x g for 3 min. 
 So 3, 75 mL (3 x) of the separate was transferred to the HiBand® DNA Midi 
column and centrifuged for 5 minutes at 6000 x g. The flow through was 
discarded.  
 The DNA was washed with 3, 5 mL of HB buffer and centrifuged at 6000 x g 
followed by discarding the flow through.  
 The DNA was further washed with DNA wash buffer and 95% ethanol and 
centrifuged at 6000 x g to discard the flow through.  
 The empty HiBand® column was centrifuged for removal of excess ethanol 
 The DNA was eluted using 0, 5 mL of DNA elution buffer and centrifugation at 
6000 x g to elute the DNA. 
 The eluted DNA was stored at -20 o C until used for PCR 
 
 DNA extraction using Qiangen DNA Mini Kit 
 
Protocol D was used for genomic DNA isolation for Gran positive bacteria and included 
the following steps: 
The overnight cultures that are described above were centrifuged for 10min at 8000x g 




 The pellets were re-suspended in 180 µL (20 mg/mL) lysozyme solution and in-
cubated at 37 o C for 30 min 
 A volume 20 µL of proteinase K and 200 µL of Buffer AL were added after incu-
bating as described in product manual  
 The mixtures were further incubated at 56o C for 30 min and at 95o for 15 min 
 Once incubated they were briefly centrifuged followed by adding 200 µL of 96% 
ethanol and vortex for few seconds 
 The samples were then transferred to a clean QIAamp Spin column, centrifuged 
for a few seconds again to remove ethanol and further adding 500 µL of buffer 
AW1 added. 
 They were centrifuged at 6000 x g (8000 rpm) to remove buffer AW1 followed 
by adding another 500 µL of buffer AW2 then centrifuged at 12000 x g 
(8000rpm) for 6min to remove bufferAW2. 
 The QIAamp Spin Columns with bind DNA were inserted into a clean 1,5mL mi-
crocentrifuge tube and 200 µL of AE elution buffer were added and set to equili-
brate in 3min 
 Then columns were centrifuged at 8000 x g (8000 rpm) for 2 min to elute DNA 
and the eluted DNA was stored at -20o C until used for PCR. 
 
 DNA extraction using E.Z.N.A Bacterial DNA Kit  
 
Procedure: 
The protocol for bacterial DNA as described by product solution manual was used. 
Reagents were mixed as recommended on page 4 of this solution manual. The 
procedure included the following steps: 
 
 To begin with 3 mL of overnight cell culture was centrifuged at 4000 x g for 10 





 To re-suspend the pellet 100 µL of TE buffer was added and vortex for a few se-
conds 
            10 µL of lysozyme was added and incubated at 30 o C for 10min 
 
 After incubation 100 µL of BTL buffer and 20 µL of proteinase K were added and 
vortex thoroughly.  
 
 The samples were incubated at 55o C followed by vortexing after every 25 min 
            5 µL of RNase A was added, inverted for a few seconds and incubated at room  
           .temperature for 5 min 
      
 The samples were then centrifuged at 10000 x g for 2 min in order to pellet any 
undigested materials and transferred to a new 1.5mL microcentrifuge.  
            220 µL of DBL buffer were added, vortex and incubated at 65o C for 10 min 
  
 The samples were further transferred into a clean Hibind DNA Mini column with 
220 µL 96% ethanol and the column was inserted into a 1, 5 mL microcentrifuge 
tube and centrifuged at 10000 x g for 2 min in order to discard the flow-through. 
 
 The columns containing band DNA was centrifuged at 10000 x g for another 2 
min to remove ethanol and DNA wash buffer. 
 
 The Hibind DNA Mini columns were transferred into 1,5mL microcentrifuge 
tubes followed by adding 100 mL of pre heated (65o C) elution buffer and set to 
equilibrate for 3min. 
 
 DNA was eluted following centrifugation at 10000 x g for 2 min and was stored 









Principles of Polymerase Chain Reaction (PCR) 
 
PCR is an in vitro method used to make copies of a DNA segment and involves an 
enzymatic reaction to amplify a specific DNA sequence using complimentary 
oligonucleotide primers, dinucleotide triphosphates (dNTPs) and the DNA polymerase 
in an optimized buffer. The reaction starts with the binding of primers that hybridize to 
the opposite single stranded DNA and precedes towards the region of interest (Erlisch, 
1989).  The DNA polymerase is a thermo stable enzyme that effectively binds at 
temperatures around 72°C and extends the growing DNA. The reaction volume for PCR 
varies but sometimes 25µL can be used in PCR. The thermal cycler is a programmable 
heating block that changes in temperatures for a given number of circles. At 94°C the 
double stranded DNA denatures into single stranded DNA. This denatured DNA follows 
the binding of oligonucleotide primers to the single stranded DNA under cooling 
temperature to about 55o C. The primer binding temperature could also vary depending 
on the annealing temperature for each primer pair. After primers bind to the single 
stranded DNA, they are then extended by the work of DNA polymerase which forms a 
double stranded DNA. The process continues until the number of expected circles is 
obtained.  This process leads to an exponential generation of copies which could result 
into millions of copies being amplified from a  DNA template (Erlisch, 1989). 
 
Some guidelines for a successful PCR reaction are that: 
 
 primers are template specific and can only bind to one specific site on the 
template DNA,  
 Mg2+ concentration should be optimized so they do not compromise the binding 
of primers to the template DNA.   








Primer dilution for PCR 
 
The primer stock solution as made by adding appropriate volume of distilled water(K-
res, UiT) as recommended by product manufacturer(Eurogentec, Belgium) to obtain a 
100 pMol/µL stock solution. The stock solution was further diluted to10 pMol/µL by 
adding 90 µL of distilled water to 10 µL 100 pMol/L stock solutions. They were stored 
at - 20 o C before being use in PCR. 10pMol/L primer solutions were further diluted to 3, 
2 pMol/L. To do so, 68 µL of distilled water were added to 32 µL, 10pM/ µL primer 
solution. The solutions were stored at -20o C for use in cycle sequencing. 
 
 
PCR for detection of 16SrDNA  
 
The presence and quality of DNA was tested in all the isolates included in the study and 
involved the use of two specific primers designed to target the 16SrDNA gene. 16SrDNA 
gene encodes16SrRNA involved in protein synthesis. Therefore the presence of 
16SrDNA reflects the fact that bacterial DNA is present in the sample. The presence and 
quality of DNA was determined by agarose gel electrophoreses. The PCR reaction 
mixture and program for detection of 16SrDNA are shown in appendix (Table 3, 8) 
respectively. The PCR was performed in 25 µL of total PCR reaction mix shown in 
appendix (Table 3). 
 
PCR for screening of genes encoding potential virulence 
factors 
 
All strains including positive and negative controls were screened for genes encoding 
potential virulence factors. Conditions for PCR were the same for all the isolates. The 
master mix and composition for PCR are shown in table 1 under master mix for 
detection of gene targets. The PCR was performed according to program given in 






Performing PCR for DNA analyses and gap closure 
 
For gap closure gradient PCR was used for all the samples. The reaction mixture was the 
same for all the samples as shown in appendix (Table 3) under mix for gap closure. The 
program for gradient PCR was applied according to appendix (Table 10).  
 
 
Primer walking for DNA analyses and gap closure 
 
Primer walking was applied in order to primer-walk some specific regions of the K60-
39/3D plasmid. The decision was made after suspicion that some regions could have 
been circular or duplicated. To primer walk three reference primers were designed and 
were designated by 3D_plasmid-161bF, 3D_plasmid- 160F and 3D_plasmid160F as 
shown in appendix (Mater table B). To do so 24 µL of highly concentrated DNA (>200 
ng/µL) template was used for every PCR reaction. 3 µL of 5 x-buffers, 1µL of primer 
(50pmol/µL) and 3µL of Big-dye 3.1 were used per PCR reaction.  
 
 
Long Range PCR for DNA analyses and gap closure 
 
Long range PCRs were run in order to amplify product sizes above in the range between 
4 kb and 5kb. This method was used in order amplify unknown product sizes for gap 
closure. The PCR reaction program is shown in appendix (table 13). Primers are given in 
appendix (master table B) and the reactions are 3D_49, 3D_46, 3D_42 and 3D_36. 
Reactions were carried out according to kit description manual and the following 













LongRange PCR buffer.                                              5 µL 
dNTPs mix(10mM).                                                    2,5 µL 
Primer,A..                                                                      2,5 µL 
PrimerB                                                                        2,5 µL 
RNase-free water                                                       24 µL 
LongRange PCR enzyme mix                                  0, 4 µL 
Buffer Q                                                                        10 µL 




Principles of DNA sequencing: 
 
The DNA sequencing involved two steps. In the first step direct sequencing of PCR 
products with BigDye® Terminator v3.1 (Applied Biosystems) was carried out. In the 
second step however, the precise nucleotide sequences of the DNA fragment were 
determined by the use of automated DNA sequencing machine. In order to do so, the 
PCR products were fist purified to remove remaining nucleotides that were added to the 
growing chain during primer extension. Sequencing reactions were then carried out by 
PCR (Cycle Sequencing) before the sequences were read and determined by the ABI 
PRISM 3100 Genetic Analyser (Applied Biosystems). The genetic analyser uses a 
capillary with liquid polymers which allow smaller molecule to pass rapidly than larger 
molecules. In each fragment a modified base is incorporated during cycle sequencing 
and can be detected by a laser which is capable of distinguishing between different 
fluorescent colours. Each base is assigned its own colour: A green, T red C blue and G 
black. The detected bases are then registered on the computer which produces a 
chromatogram showing how the bases are aligned in a sequence as illustrated in Figure 





                       
 
Figure II:  The schematic representation of DNA sequencing. In (A the samples are 
loaded into the capillary and the laser reads the last incorporated base as the DNA 
fragment migrates through the capillary.  In (B the detected bases are recorded by the 











PCR for purifying of PCR products and DNA cycle sequencing 
 
Procedure:                          
The amplified PCR products were subjected to clean-up for the removal of unused 
oligonucleotides and dinucleotide triphosphates (dNTPs). To do so the following 
procedure was applied: 
A total volume of 10 µL of PCR product was inserted into PCR reaction tubes for each 
reaction  
In addition 4 µL of Exo-SAP-IT (USB, Cleveland, Ohio) was added to the reaction tubes 
The tubes were inserted into the thermal cycler (Applied Biosystems) and run at 37o C 
for 30 min in order to degrade unused oligonucleotides and dNTPs, then at 80 o C for 
another 15 min to deactivate ExoSap-IT. 
The clean-up PCR products were amplified in the thermal cycler using one primer per 
PCR (Applied Biosystem) before being used for sequence detection.  
 
Reaction mixture for sequencing: 
 
13 µL of dH2O  
3 µL of 5x buffer 
1 µL of BigDye 3, 1 (table 4) 
1 µL (3,2pMol/L), primer 
2 µL purified template 













Principles of agarose gel electrophoreses 
 
The agarose gel electrophoresis separates molecules based on size and is used to 
separate DNA molecules. In an agarose gel fragments that are larger move slowly while 
smaller fragments move faster. The movement of molecules is determined by their 
ability to penetrate the agarose gel, which is made of macromolecules that are tightly 
packed together forming a network. The smaller the molecule is, the easier it penetrates 
and larger the molecule is, the slower it penetrates.  An agarose gel electrophoresis 
involves the preparation of agarose gel, the insertion of gel into a gel chamber, insertion 
of samples and application of electric power to separate the DNA. Because DNA is 
negatively charged separation follows the movement of DNA from the negatively 
charged electrode towards the positively charged electrode. This movement in an 
electric field causes smaller molecules to move faster than larger molecules. Therefore 
the agarose gel could be used to determine sizes of molecules. A molecular ladder 
known as DNA ladder is used to compare and determine the size of unknown DNA 
fragments on the agarose gel. Agarose gel electrophoreses is easy, quicker and highly 
reproducible and above all time saving.   
 
Procedure: 
The agarose gel electrophoresis was widely used in order to detect positive PCR 
products. It was also used in detection of 16SrDNA so as to verify whether DNA was 
present in all the samples. The agarose gel electrophoreses included the following 
procedures: 
 
 A total of 1g agarose (Seakem LE agarose, Lenza, Rochland, USA) was dissolved 
in 100 mL 0, 5* TAE buffer (K-res, UiT), by boiling in the microwave for 2 
minutes 
 The solution was cooled down for a few minutes followed by adding 5µL of 
GelRed nucleic acid stain (Biotium, Hayward). 
 It was further poured into a gel chamber containing a comb and set to cool for 




 A volume of 5 µL*2 of 1 Kb+ DNA ladder (Biotium, Hayward) were loaded into 
the gel wells at both end of the of agarose gel for each reaction and 5 µL of each 
PCR product was loaded into the gel wells 
 The agarose gel electrophoreses was run at 124 V for about 45 minutes and the 




Bioinformatics analyses of sequencing results. 
 
Sequence analyses were done using various computer software programmes. Artemis 
was used for visualization of sequence features. Artemis Comparison Tool (ACT) was 
used to pairwise compare two or more sequences. EBiox was used to align sequence 
reads against the plasmid. Algorithm-based automatic contiguation of assembled 
sequence (Abacas) were used for recording sequences and BioEdit sequence alignment 






The correlation between the presence of all tested ORFs and the clinical source of 
isolates among the two populations as well as between them, was determined in a 
contingency table of Fisher`s exact test.  A p < 0, 05 was considered significant to show 































































Gap closure of trans-conjugant (TUH56-32) megaplasmid  
 
The DNA sequence of the 300 kb megaplasmid detected in blood culture isolate of E. 
faecium (K60-39), transconjugant (TUH 56-39/3D) had been obtained using next 
generation sequencing. The selected ORFs that were included in the study were present 
in this plasmid DNA sequence. To verify the linkage to the plasmid and to enable further 
studies of the plasmid, gaps closure of the plasmid DNA to obtain a circle DNA molecule 
was carried out by PCR analyses followed by DNA sequencing of PCR products. 
The Illumina DNA sequencing of the TUH 56-39/3D plasmid showed that it is composed 
of 286 kb, given in 18 scaffolds with 26 gaps and more than 60 IS (Appendix, Table 6). It 
was primarily selected because it did test positive to all four open reading frames that 
were screened in the screening project. Therefore it was used as positive control in 
addition to gap closure.  
 
 
The 286 kb DNA sequence was subjected to gap closure using 66 specific primer pairs 
as shown in appendix (Mater table B). All were used in PCR and 13 PCR positive 
reactions were obtained. In addition positive PCR products were further subjected to 
automated DNA sequencing and the sequences were again analysed and used in gaps 
closure.  The gaps closing results can be seen in the figures V-VII. Figures were taken 
from the sequence assembly in Artemis and ACT, software programs that were used in 
the study for sequence comparison and alignment. Of the 13 PCR positive reactions, 7 
were used in gaps closure. The remaining PCR products did not perfectly fit into their 





Figure V: Figure showed positive PCR reactions that were obtained. Reactions that led 
to gap closure are shown in green far right. The area below mixed in red and light green 
shows that the primer combinations were PCR positive but sequences were poor to be 







Figure VI: The blue and cyan bars in A and B show contigs of the old sequence before 
gap closure, while the yellow and green are the contigs of the new sequence after gap 
closure. The yellow lines between the old and new sequence show that the sequences 
are similar. In A) the arrows pointing upwards shows where to contigs were joined and 
the gap closed. In B) the arrow pointing downwards shows where a contig was split 






Figure VII: The green, blue and red arrows below indicate targets that are present in 
Staphylococcus aureus, but identical to those found in E. faecium. Insertion sequence 
elements are shown in light blue and light blue arrows are pointing in direction of 
primers. Shown in salmon are regions covering the aacA-aphD gene and in brown 








Figure VIII: An agarose gel electrophoreses result of the amplified plasmid DNA in 
transconjugant TUH56-32. Primers that were used included: 1. 161bF/162R, 3. 
187F/188R, 4. 204R/209bF, 5. 209bF/205R. The results 1 through 8 were obtained 






Figure IX: An agarose gel electrophoreses result of the amplified plasmid DNA in 
transconjugant TUH56-32. Primers that were used included: 1. 161bF/162R, 3. 













Screening of the 150 isolates 
 
The ORFs harbored by a megaplasmid from a blood culture isolate of E. faecium and 
encoding hypothetical proteins with a signal peptide for secretion and with unknown 
function were selected for prevalence analyses in an enterococcal strain collection. The 
prevalence of four ORFs in the strain collection was investigated by PCR analyses. 
Screening results for the detection of genes encoding potential virulence factors in blood 
cultures, other clinical and non-clinical isolates of E. faecium and E. faecalis are 




Distribution and sources of isolates 
 
The strain collection consisted of 150 isolates including 116 E. faecium and 34 E. faecalis 
(Figure 1). All were screened for presence of ORFs using specific primers for each ORF 
as given in appendix (Table 4). Isolates were assigned into three different categories and 
included isolates of blood cultures, other clinical isolates and non-clinical isolates. Other 
clinical isolates included those of human wounds, urine and human faeces from hospital 
outbreak. Non-clinical isolates however were derived from faeces community outbreak 
of enterococci. As shown in Figure 1 none of E. faecalis isolates were derived from non-





Figure 1: The distribution of isolates that were used in this study.  
 
 
Prevalence of ORFs in E. faecium compared to E. faecalis 
 
The distribution of positive and negative test results among E. faecium and E. faecalis is 
given in Figure 2. The PCR test results presented show that 23(68%) out of 34 E. faecalis 
isolates were negative to all four ORFs compare to 14(12%) out of all 116 E. faecium (p> 
0, 0001). In addition 102(87%) out of 116 E. faecium isolates tested positive to at least 







Figure 2: The distribution of positive and negative PCR test results. The negative test 
here means that the test was negative to all four gene targets. And positive test means 
that the test was positive to at least one or more targets. 
 
 
Figure 3 compares the prevalence of ORFs detected among E. faecium and E. faecalis 
strains. The test results show that ORFs were detected among E. faecium and E. faecalis 
isolates that were included, although the frequency of ORFs were not the same in each 
group. Compared to E. faecalis, ORF147, ORF117 and ORF118 were highly present 
among E. faecium isolates.  The two species differed significantly in prevalence to all 
ORFs as given in Table 14. The most prevalently detected among E. faecium was 
ORF023; while the most possessed ORFs among E. faecalis were ORF117 and ORF118. A 
































Figure 3 comparison of the different ORFs between E. faecium and E. faecalis  
 
 
Table 14: The statistical significance for presence and absence of ORFs between isolates 





 E. faecium 
 
Negative  









ORF023 89 27 2 32 0,0001 
ORF147 59 57 3 31 0,0001 
ORF117 54 62 9 25 0,0479 
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Distribution of ORFs in E. faecium  
 
To investigate the distribution of ORFs among E. faecium isolates, the number of isolates 
that were PCR positive was calculated for each ORF. Figure 4 presents the percentage 
distribution of ORFs among E. faecium. None of the isolates from non-clinical cultures 
were harboring ORF147, ORF117 and ORF118. The tested ORFs were overrepresented 
among isolates derived from blood cultures, but also highly present in other clinical 
isolates. Figures 12-13 show the statistical significance between isolates of blood 
cultures and those of other clinical and non- clinical sources. The most prevalently 
detected was ORF023 and was highly present in isolates of all sources.  
 
Significant difference was revealed between isolates of blood cultures and those of other 
clinical isolates (Table 12) with regard to ORF147 (P<0, 0003), ORF117 (0, 0, 0097) and 
ORF118 (P<0, 0046). However no significant difference in prevalence between isolates 
of blood cultures and those of other clinical and non-clinical cultures in term of ORF023 
was observed. The p values were p: 0, 4403 for isolates of other clinical and p: 1, 0000 
for isolates of non-clinical background. A statistical significance was however revealed 
between isolates of blood culture and those of non-clinical as regard to ORF147, ORF117 




Table 12: The statistical significance for presence and absence of ORFs between isolates 










Negative  OC 
 
P-value 
ORF023 53 18 25 5 0,4403 
ORF147 50 21 9 21 0,0003 
ORF117 44 27 10 20 0,0097 
ORF118 46 25 10 20 0,0046 







Figure 4: The comparison and prevalence of ORFs among E. faecium blood culture 





Table 13: The statistical significance for presence and absence of ORFs between isolates 










Negative  NC 
 
P-value 
ORF023 53 18 11 4 1,0000 
ORF147 50 21 0 15 0,0001 
ORF117 44 27 0 15 0,0001 
ORF118 46 25 0 15 0,0001 







Targets distribution among E. faecium isolates 
 
To better understand how these genes targets were distributed among E. faecium iso-
lates the PCR positive results were analyzed in terms of number of ORFs detected in 
each isolate and the  numbers of ORFs are shown in Figure 5 for the three different  
groups of E. faecium. The results show that 36 (51%) of total 71 blood culture isolates 
were harboring all four ORFs while only 4 (13%) out of total 30 other clinical isolates 
tested positive to all four ORFs. ORF023 was detected in 11 (73%) of total 15 non-
clinical isolates, but none were harboring ORF147, ORF117 and ORF118. A high number 
of negative samples to all the tested ORFs were observed among blood culture isolates. 
Significant difference was revealed between blood cultures isolates and those of other 




Figure 5: The number of E. faecium strains that were harboring 0 ORF, 1 ORF, 2 ORFs 3 





Targets distribution among E. faecalis isolates 
 
The presence and number of ORFs per isolate in each group of E. faecalis are illustrated 
in Figure 6. The numbers show that 19 (56%) out of total 27 blood culture isolates did 
not detect positive to any of the ORFs. The same show that 4 (57%) out of total 7 other 
clinical isolates were negative to all ORFs. One isolate among other clinical isolates was 
detected for all four ORFs, but none of the blood culture isolates tested positive to all 
four targets. Also 2 (29%) out of total 7 other clinical isolates were positive to three of 





Figure 6: The number of E. faecalis strains that were harboring 0 ORF, 1 ORF, 2 ORFs 3 
ORFs and 4 ORFs 
The agarose gel electrophoreses for detection of ORFs  
 
The agarose gel electrophoreses results are given for a representative collection of 
isolates that were screened for presence of all four ORFs. Figure 7 shows results over all 
CC17 and CC 2 strains that were included in the study. It was obtained for the second 
time to verify whether the previously tested CC 17 and CC 2 strains that were positive 
actually could test positive in the verification test. The positive control was positive and 
negative control also negative throughout the test. The fidelity of the control samples 
was very crucial as it allowed for better judgment as to whether the tested samples were 
negative or positive. Figures 8-11 were obtained after an agarose gel electrophoreses 





Figure 7: An agarose gel electrophoreses results for genes encoding potential virulence 
factors in clonal complex 17 and 2(mater table A) strains that were included in this 
study. Targets were ORF147, above and ORF118 below. Samples 1, 2 above and far left 
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were positive and negative controls respectively. The agarose gel was re-run in order to 
verify that previously tested clonal complexes were actually positive or negative for the 
tested targets 
 
Figure 8: An agarose gel electrophoreses results of ORF023. Sample 1, 2 were positive 






Figure 9: An agarose gel electrophoreses results ORF147. Sample 1, 2 were positive and 




Figure 10: An agarose gel electrophoreses results of ORF118. Sample 1, 2 were positive 




Figure 11: An agarose gel electrophoreses results of ORF117. Sample 1, 2 were positive 



























































Plasmid sequencing and gap closure 
 
 
In this section, the pLG1 replicon type plasmid originating from E. faecium (K60-39/3D) 
had been studied. The aim of the study was to obtain a circular map as well as study the 
genetic content of the pLG1 replicon type megaplasmid from E. faecium (K60-39). 
Primers were designed in order to amplify sequence targets and to assemble two and 
two contigs into one (closed gap). The assembly was done by amplification carried out 
on the PCR machine (Table 5) and PCR products were further analysed in terms of sizes 
and quality based on agarose gel electrophoreses results (Figure VI, VII), before they 
were purified and sent for sequencing. Sequencing results were then analysed and used 
to confirm the sequence in gap closure.  
 
The 3D megaplasmid is described as narrow host range plasmid and has been 
exclusively found among E. faecium population (Laverde Gomez et al., 2011). The reason 
of obtaining a genetic map is that it can be used in future comparative genomics. If 
obtained the K60-39/3D plasmid could have been used to study genes content and 
furthermore determine whether all the ORFs detected in this study were intact. 
However, the gap closing project has been a challenging encounter from the very 
beginning; and so the circular DNA was not obtained because of several reasons.  
 
 
Unspecified primer binding  
 
As shown in Figure IX the result of unspecific primer binding led to the acquisition of 
multiple bands on the agarose gel and for most of these products it was increasingly 
difficult to obtain a precise DNA of interest. Three methods could have been 
implemented to obtain the amplified DNA: 1. by purifying DNA from the gel band, 2 by 
applying gradient PCR and 3 by optimizing PCR reaction conditions. Both gradient PCR 
and optimization of PCR reaction conditions were implemented. The agarose gel 
electrophoreses results in Figure VIII was obtained from gradient PCR. The second 
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method was not used in this study because the sizes of some gaps were unknown and 
moreover, it was extremely time consuming. For double bands that were present on the 
agarose gel following agarose gel electrophoreses, optimization of reaction conditions 
was implemented, but was not effective because the primers used were of different 
annealing temperatures for each pair. The gradient PCR also did not work because 
different annealing temperatures were given for most of the primers that were used. 
 
 
Insertion sequence elements 
 
Moreover, the presence of many insertion sequence elements was also put into question 
as to whether they may have cause failure in gap closure. For example, the gene 
encoding aminoglycoside modifying enzymes was shown to have been engulfed by 
insertion sequence elements, IS 256 (Figure Appendix) on both sides and could have 
potentially knock out this region to form an extra plasmid. In this case it could make the 
PCR fragments useless because there will be no gaps to fill them into due to the fact that 
the entire region has been knocked out. 
 
The aacA-aphD gene 
 
It was also assumed that the gene (aacA-aphD) encoding aminoglycoside modifying 
enzyme in enterococci was present and may have been duplicated (Figure VII). 
Considering that was the case it would have meant that two identical fragments would 
be lying adjacent to each other or far apart. Have they been distance apart from each 
other it would cause the pasted sequence to move back and forward in the direction of 
both fragments as was observed in this study (Figure VI). Two different methods were 
applied in order to fix these problems. One was the use of direct sequencing of the DNA 
so that sequences could be used to cover regions between identical genes that were 
thought of being far apart. The second method however was the used of long range PCR 
for the same purpose as direct sequencing. Because the sequencing machine could not 
properly read sequences above one-thousand base pairs, both methods were not further 




Unsuccessful PCRs reaction 
Another possible problem was due to the lack of enough positive PCRs reactions to be 
included in gaps closure. Out of 66 PCR reactions, only 13 were PCR positive and good 
for use in sequencing. Of these 7 (Figure V) were selected and used in gap closure. It was 
not clear what caused these negative PCR reactions, but it was speculated that they 
could have been because of poor primer quality or that during the time primers were 
designed it was not easy to predict overlapping contigs.  In addition the product sizes for 
most positive PCRs were above one-thousand base pairs, but during the time of 
sequencing not more than five-hundred base pairs were obtained for most of the 
sequences. Any reads above five-hundred were of poor quality for most of the 
sequences. The sequencing machine used could only sequence up to one-thousand base 
pairs in one reaction. The result of this however, was that several positive PCRs were 
needed to close gaps that were bigger than one-thousand base pairs. With little time left 
for laboratory work this was not an option. Furthermore, an increasing number of 
primers did not bind specifically to their target sites (Figure VII), which lead to unclean 
PCR products and further into poor DNA sequences.  
 
Detection of ORFs and prevalence determination 
 
 
Although Enterococci are commensals of the human gut flora; their ability to cause 
infection cannot be neglected. They are implicated in hospital acquired infections and 
are ranked Europe`s 4th most common cause of hospital acquired infections (Hidron et 
al., 2008). That being said, virulence factors are also common among enterococcal 
species. The ability of pathogens to invade bloodstream requires that they have the 
mechanism to resist the host immune system. In this study, results were obtained for 
four selected ORFs with potential immune invasive properties. 
 
Investigation has being made on the prevalence of OFRs with potential virulence 
properties in enterococci causing infectious diseases and those that are commensal of 
the human and animal gut flora. The observed prevalence of ORF023 among E. faecium 
isolates was quite high in the strain collection (Figure 4). Compare to other ORFs it was 
the most detected among E. faecium of all sources. There was no statistical significance 
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in prevalence of ORF023 between isolates of blood cultures and those of other sources. 
This highlights the fact that ORF023 could have been of little or no clinical significance 
due to its abundance in non-clinical culture isolates (76%).  Interestingly, prevalence did 
not differ from blood culture isolates, although the result was not expected. Because of 
these findings it was concluded that blood culture isolates of E. faecium could have 
possessed ORF023 for other unknown purposes then what was previously proposed, 
which is immune invasion and host colonization. The presence of ORF023 among non-
clinical isolates also highlights the possibility of its role in colonization of the 
gastrointestinal tract, given its frequency in non-clinical isolates of human and animal 
fecal  as shown in appendix (Master table A).  
 
The prevalence of ORF147 was higher among blood culture isolates than among other 
clinical and non-clinical isolates as the results in Figure 4 indicate. None of the isolates 
obtained from non-clinical sources detected positive to ORF147. Therefore the lack of 
ORF147 among non-clinical isolates, but presence in isolates from blood and other 
clinical sources shows that ORF147 could have been a marker for isolates obtained from 
blood cultures and other clinical sources, but not isolates of non-clinical origin.    
 
It was shown that ORF117 and ORF118 were most prevalent in isolates of blood 
cultures compare to other clinical sources. A statistical significance was revealed 
between isolates of blood cultures and those of other origins. None of these ORFs were 
detected among isolates of non-clinical origin. Their absences among non-clinical 
isolates, but presence in isolates of blood cultures and other clinical cultures also 
highlights the fact that they could have been clinical markers and therefore have 
potential virulence properties. However, further investigation might be needed in order 
to conclude whether they do play a role in immune invasion and host colonization.   
 
The prevalence of ORF147, ORF117 and ORF118 differed between isolates from blood 
cultures and those of other clinical sources and statistical significance was revealed 
indication that the tested ORFs were more present among blood culture isolates 
compared to those of other clinical sources (Table 12). Statistical significance was 
shown for presence of all ORFs detected in each isolate between blood cultures and 
other clinical isolates (P< 0, 0004).  
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E. faecium versus E. faecalis 
 
On the population level E. faecium seems to outnumber E. faecalis in the clinical settings 
(Treitman et al., 2005). This transition of E. faecium could have global implication in 
terms of disease management and antimicrobial resistance control. Therefore it is 
important to study these recent trends and so as to take possible measures in tackling 
the spread of high-risk pathogens of E. faecium. It is assumed that the growing 
mobilization of E. faecium into high-risk pathogens has to do with their ability to acquire 
and spread mobile genetic elements (Rosvoll et al., 2010). Therefore  on the species level 
E. faecium are said to contain more plasmids than E. faecalis (Rosvoll et al., 2010). By 
considering E. faecium and E. faecalis, E. faecium has the largest genome (Tettelin et al., 
2008). However larger genome means that the bacterial can have elevated capacity to 
add on foreign genetic materials. The ability has been tested in many studies (Duprè et 
al., 2003, Oancea et al., 2004, Rosvoll et al., 2010). The ability to acquire and disseminate 
genetic elements might have been the driving force behind E. faecium popularity in 
hospital environments in recent years. In this thesis E. faecium of blood, other clinical 
and non-clinical origins had been compared with E. faecalis derived from blood and 
other clinical cultures in order to see if the prevalence of genes encoding potential ORFs 
with immune invasive and host colonization properties was to be more in E. faecium 
than E. faecalis. The comparison between E. faecium and E. faecalis showed that E. 
faecium were most detected for presence of all four ORFs. The reason for this trend 
could have been because the selected ORFs were only selected from blood cultures 
isolates of E. faecium and not E. faecalis. The results in Table 14 show that E. faecium 
differs significantly in presence of all four ORFs. Based on the assumption that the tested 
ORFs were not derived from blood cultures isolates of E.faecalis the need for further 
investigation should be inevitable in deciding whether the two species differ in 
prevalence to the studied ORFs. However, this would need to be elucidated in the near 
future in order to make any final conclusion. Until then, the current results showed the 









In this thesis an attempt has been made to address two important aspects of enterococci 
with main focus on E. faecium. An attempt to obtain a circular map of a pLG1 replicon 
type plasmid in an E. faecium strain failed following several unidentified problems. It 
was not easy to identify one specific cause of the problems except that the factors 
discussed above were thought to have been involved. Because of time limit, not more 
has been done to resolve these problems. For future study test should be done to assure 
that the primers are working to avoid unsuccessful PCRs and that the sequencing 
machine is capable of producing good sequences. 
 
For the screening experiment the clinical significance of all ORFs are unknown and 
would there have to be elucidated in the nearest future. However, it has been revealed 
that the selected ORFs were significantly more common among isolates of blood cultures 
of E. faecium compared to those derived from other sources. Isolates of non-clinical 
cultures were not harbouring ORF147, ORF117 and ORF118. Differences in prevalence 
were significant between non-clinical isolates and isolates from other clinical sources, 
except for ORF023 which did not differ in prevalence among E. faecium.  A significant 
number of Isolates among blood cultures were positive to all four ORFs. In addition 
ORFs were also more prevalent but and statistically significant different between 
isolates of E. faecium and E. faecalis. In conclusion, the tested hypothesis was correct 
that the selected ORFs were highly prevalent in blood cultures isolates of E. faecium 
compare to isolates of other human cultures. The selected ORFs were derived from 
blood culture isolates of E. faecium. With that being said, further studies might be 
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Table 3: PCR master mixes used in this study 
Master mix     for detection of 16SrDNa                                                       Amount (µL) 
TagRed Ready Mix 12,5  
dH2O                                                                                                                     9,0  
16S R primer                                                                                                        1,0  
16S F primer                                                                                                        1,0 
DNA template                                                                                                      1,0  
Master mix for detection of genes target                                                      Amount(µL) 
 
TagRed Ready Mix  12,5  
dH2O.                                                                                                                     9,5  
R primer.                                                                                                               0,5  
F primer.                                                                                                                0,5  
DNA Template.                                                                                                     2.0    
Master mix for gap closing                                                                              Amount(µL) 
TagRed Ready Mix  12,5  
dH2O                                                                                                                      9,5  
R primer.                                                                                                               0,5  
F primer.                                                                                                                0,5  









Table 4:  Shows screening primers, their melting temperature™ expected product sizes 
and name of ORFs encoding hypothetical proteins 






  TM 
5'-TGGGGGCTATTTTCTTTTGA-3' 
 5'CGAAATAGCGTTGGAATCAGT-3' 
118 2C F 










5'-GGT GTT TCT GTT GGG CTA CTT AT-
3' 
5'-GTT GGC TTG ATT TAC ATT TCC 
TAC-3' 
117 2C F 






                      
519bp                    
45,3 
41,4 
 5'-CTT TAG ATA GGG ACG GAA TAG C-
3' 
 5'-TTT TCT TTC CAA TTC CGT GAT-3' 
147 2C F 







                       
                    






023 2C F 










Based on Signal P analysis, it was projected that the following gene targets encode 
hypothetical proteins with signal peptides sequences. 
 
Table 6 Illumina DNA sequencing results of the 3D megaplasmid of E. faecium (K60-39) 
                 Variables                  Data 





Number of scaffolds 
GC content (%) 
CDS 
IS elements 
Number of gaps  
Number of gaps closed 
Primers available 
Number PCRs run 
                 300 
                 3D 
                 Mate paired assembly 
                 286        
                 18 
                 34,24 
                 315 
                 60 
                 26 
                  7   
                 71 







Table 5: Reagents and materials that were used in the study 
Reagents Amount/PCR Source 
RED Taq DNA Polymerase Ready Mix(2x Master Mix Kit) 
Comp: 
75  mM Tris-HCl pH 8.5 
20  mM (NH4)2SO4 
0,2 mM of each dNTP 
1,5 mM MgCl2 
0,01% Tween 20 
0,625 units/µl VWR Tag polymerase 










Reaction Master Mix 
Comp: 






BigDye 3.1 Reaction Kit 
Comp: 
Ready  Reaction Mix 
pGEM®-3Zf(+) double-stranded DNA template 
21 M12 control primer 









QIAGEN Long Range PCR kit 
Comp: 
Long Range PCR buffer 
dNTPs(10mM) 
RNase-free water 
Long Range PCR Enzyme Mix 









Exonuclease 1and Shrimp Alkaline Phosphatase in 










TAE buffer 1X 
40 mM.  Tris-HCl (Triza-base) 
20 mM.  acetic acid 




1 Kb+ DNA Ladder 
 











Materials   
GeneSnap Version 7.12  - Syngene, UK 
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BioEdit - Ibis, 
Bioscience 





Primers for gaps closure - Eurogentic 
S.A, Belgium 
ART, Aerosol Resistant tips  San, Diego 
California, 
USA 
ABI PRISM 3700 DNA Analyser - Applied 
Biosystems 






Table 7: Shows PCR reaction program for Screening of genes encoding potential 
virulence factors in E. faecium and E. faecalis 
 Temperature (oC)  Time Number of cycles 
   
Initial denature 95 5 min 
Denaturation 95 30 s  
25 cycles Annealing  56 30s 
Extension  72 30s 
 Final extension  72  5min  
 End of PCR  12  indefinate  
 
Table 8: Shows PCR reaction program for the detection of 16SrDNA 
 Temperature (oC)  Time Number of cycles 
    
Initial denature 95 5 min 
Denaturation 95 1 min  
30 cycles Annealing 58 1min 
Extension 72 1min 
 Final extension  72  5min  





Table 9: Cycle sequencing protocal for clean-up PCR products 
 Temperature (o C)  Time Number of cycles 
   
Initial temperature 95 5 min 
Denaturation Tem: 95 1 min  
30 cycles Annealing Tem: 50 1 min 
Extension Tem: 60  2 min 
 Final extension  60  5min  
 End of PCR  12  indefinate  
 
 
Table 10: Gap closing PCR reaction program 
 Temperature (oC)  Time Number of cycles 
   
Initial temperature 95 5 min 
Denaturation  95 1 min  
30 cycles Annealing(gradient)  55-60 1min 
Extension Tem: 72 1min 
 Final extension  72  5min  
 End of PCR  12  indefinate  
 
Table 11: Gap closing Long Range PCR reaction program 
 Temperature (oC)  Time Number of cycles 
   
Initial 
temperature 
93      3 min 
Denaturation  93      15 s  
30 cycles Annealing  62      30 s 
Extension Tem: 68      1 min/kb 
Final extension  68       5min  
 End of PCR 12       indefinate  
 
Master table A: 
ID/fryse
stock 











229710 E.faecalis 6 (2) Urine 1992 Portugal Mikalsen et al, 2013 + 0 0 1 0 
TUH 
50-66 
UW1833 E.faecalis 40(40) Urine 1998 Germany Mikalsen et al, 2013 + 0 1 0 1 
11-E-4 50710071 E. faecalis ND Urine 2013 Norway K-Res + 0 0 0 0 
TUH 
50-58 
1638/07 E faecalis 40(40) Urine 2007 Denmark Mikalsen et al, 2014 + 0 0 0 0 
TUH 
50-59 





E faecalis 40(40) Urine 1996 Poland  Mikalsen et al, 2014 + 0 0 0 0 
TUH 
50-57 
916/07 E.faecalis 40(40) Faeces 2007 Poland  Mikalsen et al, 2013 + 1 1 1 1 
K58-54 11290601 E.faecalis NY Human blood 2008 Norway Rosvoll et al 2013 + 0 1 1 1 
TUH 
50-55 





E.faecalis 6 (2) Human blood 2006  
Netherlands 
Mikalsen et al, 2013 + 0 0 1 1 
TUH 
50-54 
340/07 E.faecalis 6 (2) Human blood 2006 Poland  Mikalsen et al, 2013 + 0 0 1 1 
TUH 
50-69 
UW7001 E faecalis 6 (2) Human blood 2006 Germany Mikalsen et al, 2013 + 0 0 1 1 
K58-45 et7 E.faecalis 21 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 1 1 
K58-55 92774 E.faecalis 28 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 1 1 
K58-37 41996 E faecalis 6 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K58-42 8569 E faecalis 245 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K58-44 et2 E.faecalis 447 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K58-46 et8 E.faecalis SLV 
av 451 
Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K58-48 et25 E.faecalis 448 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 1 
K58-49 10024691 E.faecalis 451 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K58-57 62883 E faecalis 30 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K58-62 50095526 E.faecalis 273 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K58-71 908301544 E faecalis 449 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K58-72 908302487 E.faecalis 450 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K58-77 656406 E faecalis 21 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K58-78 658545 E faecalis 16 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K59-02 75753 E faecalis 268 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
 
K59-04 691 E.faecalis 55 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K59-06 16301 E faecalis 179 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K59-08 34425 E.faecalis SVL 
av 16 
Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
K59-09 35015 E.faecalis 211 Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K59-12 141080727
5 
E faecalis SVL 
av 30 
Human blood 2008 Norway  Rosvoll et al 2013 + 0 0 0 0 
K59-13 141081343
5 
E.faecalis 28 Human blood 2008 Norway Rosvoll et al 2013 + 0 0 0 0 
TUH 2-
06 
V583 E faecalis 6(2) Human blood 1981 USA   + 0 0 0 0 
     34             2  3  9  10 
               
Strain ID Name  Skpecies ST Source Year Origin Reference 16SrRNA ORF023 ORF147 ORF1172 ORF118 
               
K59-17 18317 E. faecium 22 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K60-42 1410820462 E. faecium 22 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K59-44 43134 E. faecium 32 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K59-49 129766 E. faecium 32 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K59-19 36488 E. faecium 296 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K59-46 64750 E. faecium 533 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K60-09 506120 E. faecium 579 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K60-21 87205 E. faecium 580 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
K60-25 18580 E. faecium 581 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 0 0 
TUH 50-45 U0229/O0160/506619 E. faecium 17 Human 
blood 
1995 The Netherlands Mikalsen et al, 2014 + 1 0 0 1 
TUH 50-65 VRE-10 E. faecium 17 Human 
blood 
2004 Denmark Mikalsen et al, 2014 + 1 0 0 0 
TUH 51-67 E1463/A5FLR(vre) E. faecium 17 Human 
blood 
1998 Spain Mikalsen et al, 2014 + 1 0 0 0 
K59-67 50103605 E. faecium 18 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 1 0 0 
K59-57 10527341 E. faecium 38 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 0 0 0 
K60-02 908301850 E. faecium 52 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 0 0 0 
K59-26 et10 E. faecium 94 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 0 0 0 
K59-48 115920 E. faecium 94 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 0 0 0 
K59-50 908900774 E. faecium 202 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 1 0 0 
K59-52 10181971 E. Faecium 576 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 0 0 0 
K45-11 O2T878 E. faecium 17 Human 
blood 
1998 Sweden  + 1 1 0 0 
K60-36 1410804500 E. faecium 18 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 0 0 
K60-29 31229 E. faecium 19 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 0 0 
K59-58 10852801 E. faecium 132 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 1 0 0 
K60-40 1410811268 E. faecium 202 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 1 1 
K59-71 50117412 E. faecium 203 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 0 1 1 0 
K59-55 10454581 E. faecium 279 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 0 1 1 
K59-73 50150755 E. faecium 440 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 0 0 1 
K59-18 21864 E. faecium 574 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 1 1 0 
11-C-4 50708930 E. faecium ND Human 
blood 
2012 Norway Linezolid, Ålesund + 1 1 0 0 
K59-28 20575 E. faecium 17 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 1 0 1 
K60-27 27719 E. faecium 18 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 0 1 1 1 
K59-30 22135 E. faecium 192 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 0 1 1 1 
K60-22 14473 E. faecium 202 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 0 1 1 
K60-26 26495 E. faecium 202 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 0 1 1 1 
K59-37 14944 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 0 1 
K59-27 et20 E. faecium 17 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 1 1 1 
K59-63 79932 E. faecium 17 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-08 657214 E. faecium 17 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-13 20167 E. faecium 17 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-20 73323 E. faecium 17 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-30 39254 E. faecium 17 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-33 1410803517 E. faecium 17 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
TUH 50-68 UW6900 E. faecium 17 Human 
blood 
2005 Germany Mikalsen et al, 2014 + 1 1 1 1 
K59-51 10146163 E. faecium 18 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-15 40648 E. faecium 18 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-22 29966 E. faecium 78 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-77 50154026 E. faecium 78 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-78 7101 E. faecium 78 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
TUH 50-48 U0262/X2209 E. faecium 78 Human 
blood 
2002 The Netherlands Mikalsen et al, 2014 + 1 1 1 1 

















































K59-34 104499 E. faecium 192 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-42 36783 E. faecium 192 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 1 1 1 
K60-12 9339 E. faecium 192 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-14 38459 E. faecium 192 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-39 1410810681 E. faecium 192 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-05 653294 E. faecium 202 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-20 5977 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-21 20641 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-25 418541 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-29 20972 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-32 54271 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-33 78135 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-40 30697 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-54 10403171 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-04 651578 E. faecium 203 Human 
blood 
2008 Norway  Rosvoll et al, 2012 + 1 1 1 1 
K60-31 1410801937 E. faecium 203 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-62 81163 E. faecium 282 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-16 89332 E. faecium 440 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-36 5282 E. faecium 575 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K59-68 50108366 E. faecium 577 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
K60-07 656443 E. faecium 578 Human 
blood 
2008 Norway Rosvoll et al, 2012 + 1 1 1 1 
  71         53 50 44 46 
 
 
            
ID Name Species ST Soruce  
+ 










TUH 12-01 C68 E.faecium 16 human clinical specimen + 1996 USA (Carias et al., 1998) + 1 0 0 0 
TUH 32-62 E0510 E. faecium 17 human clinical specimen + 1998 Australia  Willems, R. J. L. + 0 1 0 1 
TUH 50-62 VRE-106 E. faecium 78 Urine + 2007 Denmark Mikalsen et al, 2014 + 0 0 0 0 
TUH 07-15  E. faecium 16 human clinical specimen + not 
available 
USA (Dahl et al., 1999) + 1 0 0 0 
TUH 02-18  E. faecium 17 human clinical specimen + 1996 Norway (Dahl et al., 2003) + 1 0 0 0 
TUH 07-55  E. faecium 17 human clinical specimen + not 
available 
Germany (Dahl et al., 1999) + 1 0 0 0 
TUH 32-74 E0300 E. faecium 20 human clinical specimen + 1994 USA Willems, R. J. L. + 1 0 0 0 
TUH 32-78 E0125 E.faecium 21 human clinical specimen + 1995 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 32-63 E1626 E.faecium 92 human clinical specimen + 1965 The 
Netherlands 
Willems et al, 2011 + 1 0 0 0 
TUH 12-04 A0885 E.faecium 308 human clinical specimen + 1996 USA (Carias et al., 1998) + 1 0 0 0 
TUH 04-65 A0884 E. faecium 313 human clinical specimen + not 
available 
USA (Dahl et al., 1999) + 1 0 0 0 
TUH 02-13  E.faecium                     
ND 
human clinical specimen + 1996 Norway  (Haarr et al., 1998) + 1 0 0 0 
TUH 41-64 U37 E.faecium                     
ND 
human clinical specimen + 1996 USA (Grady and Hayes, 
2003) 
+ 1 0 0 0 
K08-50  E.faecium                     
ND 
human clinical specimen + 2001 Norway Rosvoll et al. 2010 + 1 0 0 0 
TUH 32-56 TX0016 
(DO) 
E.faecium 18 human clinical specimen + 1992 USA Arduino et. Al., 1994 + 1 1 0 0 
TUH 32-64 E0013 E. faecium 18 human clinical specimen + 1992 UK Willems, R. J. L. + 0 0 1 1 
9-C-2 50660268 E.faecium                     
ND 
Urine + 2012 Norway K-Res + 1 1 0 0 
K08-45  E.faecium                     
ND 
human clinical specimen + 2003 Norway  Rosvoll et al. 2010 + 1 0 1 1 
TUH 50-50 NIZP292/0
2 
E.faecium 17 Wound + 2002 Poland  Mikalsen et al, 2014 + 1 0 1 1 
10-B-6 50691662 E.faecium                      
ND 
Urine + 2013 Norway K-Res + 1 1 1 1 
TUH 32-69 E0470 E.faecium                      
16* 
human faeces hospital 
outbreakspital 
+ 1999 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 32-72 E0155 E.faecium                      
17* 
human faeces hospital 
outbreakspital 
+ 1995 USA Willems, R. J. L. + 1 0 0 0 
TUH 32-75 E0073 E.faecium 22 human faeces hospital 
outbreakspital 
+ 1995 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 32-79 E0729 E.faecium 5 human faeces hospital 
outbreakspital 
+ 2000 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 32-73 E1652 E.faecium                     
18* 
human faeces hospital 
outbreakspital 
+ 2002 The 
Netherlands 
Willems, R. J. L. + 0 0 1 1 
K55-27 K55-27 E.faecium 78 faeces + 2008 Sweden Mikalsen et al, 2014 + 0 1 1 1 





+ 2013 Norway K-Res + 1 1 1 0 
11-A-3 50705414 E.faecium                    
ND 
 2013 USA K-Res + 1 1 1 1 
10-C-9 50698098 E.faecium                    
ND 


















































 2013 Norway K-Res + 1 1 1 1 
 
 
Total 30       25 9 10 10 
TUH 44-31 A0888 E. faecium 311  1998 Norway (Johnsen et al., 2005) + 0 0 0 0 
TUH 44-39 A0249 E. faecium 241  1999 Norway  (Johnsen et al., 2005) + 0 0 0 0 
TUH 44-23  E. faecium 8 human faeces community  1998 Norway (Johnsen et al., 2005) + 0 0 0 0 
TUH 45-03 A0889 E. faecium 312 human faeces community  1998 Norway (Johnsen et al., 2005) + 0 0 0 0 










human faeces  
1 1999 Norway (Johnsen et al., 2005) + 1 0 0 0 
TUH 44-50 A0251 E. faecium 195 1 1998 Norway (Johnsen et al., 2005) + 1 0 0 0 
TUH 45-12 A0886 E. faecium 309 1 1999 Norway (Johnsen et al., 2005) + 1 0 0 0 
TUH 45-30  E. faecium 247 1 1999 Norway (Johnsen et al., 2005) + 1 0 0 0 
TUH 32-67 E0403 E. faecium 7 human faeces community 1 1997 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 32-68 E0996 E. faecium 47 human faeces community 1 1998 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 32-80 E0092 E. faecium 6 human faeces community 1 1997 The 
Netherlands 
Willems, R. J. L. + 1 0 0 0 
TUH 41-67  E. faecium 18* human faeces community 1 2002 Italy (Biavasco et al., 2007) + 1 0 0 0 
TUH 44-47  E. faecium 246 human faeces community 1 1999 Norway (Johnsen et al., 2005) + 1 0 0 0 





60 human faeces community 1 1998 Norway (Johnsen et al., 
2005) 
+ 1 0 0 0 
 Total  15        11 0 0 0 
 
Master table B: Primers used in gap PCR 
5' contig primer T
m 







3D_Plasmid_006.rev   3D_Plasmid_202.rev   3D_1 
atggtggatctttagctggaa 59 43 aaggcgaaaagacaaataag
ga 
59 37   
3D_Plasmid_079.rev   3D_Plasmid_231.rev   3D_2 
tcacatctatgcattgacactca 59 39 atcgtgaccccagcattaga 60 50   
3D_Plasmid_112.forw   3D_Plasmid_266.forw   3D_3 
gaatgccaactgcgatatga 60 45 tttcgacccaccgtttattc 60 45   
3D_Plasmid_147.forw   3D_Plasmid_225.forw   3D_4 
gctcgaatagcagggaacg 61 58 cgccatcgataaacgattca 62 45   
3D_Plasmid_148.rev   3D_Plasmid_198.forw   3D_5 
ggctacacaaagaatttcaaca
ga 
60 38 gcaagcacagtaagtgtacgg 59 53   
3D_Plasmid_114.forw   3D_Plasmid_112.forw   3D_6 
cctgttgttccttggcgtat 60 55 gaatgccaactgcgatatga 60 45   
3D_Plasmid_114.forw   3D_Plasmid_266.forw   3D_7 
cctgttgttccttggcgtat 60 55 tttcgacccaccgtttattc 60 45   
3D_Plasmid_002.forw   3D_Plasmid_155.rev   3D_8 
attggatacgtggcttttgg 60 45 gaacgaaatactgaaccccaa
g 
60 45   
3D_Plasmid_002.forw   3D_Plasmid_159.forw   3D_9 
attggatacgtggcttttgg 60 45 tctgacggcttattcggagt 60 50   
3D_Plasmid_001.rev   3D_Plasmid_155.rev   3D_10 
tggctatcagttaactcacgatt 58 39 gaacgaaatatgaaccccaa
g 
60 45   
3D_Plasmid_001.rev   3D_Plasmid_159.forw   3D_11 
tggctatcagttaactcacgatt 58 39 tctgacggcttattcggagt 60 50   
3D_Plasmid_083.rev   3D_Plasmid_114.forw   3D_12 
ccagcacacacgatgaaact 60 45 cctgttgttccttggcgtat 60 55   
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3D_Plasmid_083.rev   3D_Plasmid_244.forw   3D_13 
ccagcacacacgatgaaact 60 45 catttcgatgccagatttga 60 40   
3D_Plasmid_083.rev   3D_Plasmid_266.forw   3D_14 
ccagcacacacgatgaaact 60 45 tttcgacccaccgtttattc 60 45   
3D_Plasmid_312.forw   3D_Plasmid_006.rev   3D_15 
cgatcagttttgaggaaatgaa 59 36 atggtggatctttagctggaa 59 43   
3D_Plasmid_274.rev   3D_Plasmid_277.rev   3D_16 
tgttacgatctccccaccat 60 50 agcggagtttgcgtcaatta 61 45   
3D_Plasmid_272.forw   3D_Plasmid_312.forw   3D_17 
cacgctattgccgatctttc 61 55 cgatcagttttgaggaaatga
a 
59 36   
3D_Plasmid_123.rev   3D_Plasmid_274.forw   3D_18 
tgcttagggtcaccgatctt 60 50 agagatccaaacggcgttac 59 50   
3D_Plasmid_227.forw   3D_Plasmid_245.rev   3D_19 
gccttagttgtcggtcttcg 60 55 cttcaaggataggttgccatt 58 43   
gccttagttgtcggtcttcg 60 55 cacgctattgccgatctttc 61 55 3D_20 
 
Master table B: Primers used in gap PCR 











3D_Plasmid_226.rev   3D_Plasmid_312.forw   3D_21 
gaactacggggatagcttgg 59 55 cgatcagttttgaggaaatgaa 59 36   
3D_Plasmid_202b.rev   3D_Plasmid_006b.rev   3D_22 
ttgtgcttctcccgaacttt 60 45 gattatttctgcgccagcat 60 45   
3D_Plasmid_312.forw   3D_Plasmid_272.forw   3D_23 
cgatcagttttgaggaaatgaa 59 36 cacgctattgccgatctttc 61 55   
3D_Plasmid_270.forw   3D_Plasmid_269.rev   3D_24 
gaaatagtacagatgtcgtaatg
a 
51 33 cgaatagctggtccaaaactatg 44 53   
3D_Plasmid_109.rev   3D_Plasmid_108.forw   3D_25 
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tggtgccattacacataaaagg 60 41 ctacacaactccgcaaatcg 59 50   
3D_Plasmid_147.forw   3D_Plasmid_153.forw   3D_26 
gctcgaatagcagggaacg 61 58 tgccatatctactccccctct 60 53   
3D_Plasmid_161.forw   3D_Plasmid_162.rev   3D_27 
gctataaacccaaatgaactgg 58 41 gcggtatccaggagttcatt 59 50   
3D_Plasmid_160.rev   3D_Plasmid_114.rev   3D_28 
aagacaaatgcacggtttaga 57 38 ccataggggctgtgtcaagt 60 55   
3D_Plasmid_114.forw   3D_Plasmid_266.forw   3D_29 
cctgttgttccttggcgtat 60 55 tttcgacccaccgtttattc 60 45   
3D_Plasmid_114.forw   3D_Plasmid_244.forw   3D_30 
cctgttgttccttggcgtat 60 55 catttcgatgccagatttga 60 40   
3D_Plasmid_114.forw   3D_Plasmid_244.forw   3D_31 
cctgttgttccttggcgtat 60 55 catttcgatgccagatttga 60 40   
3D_Plasmid_199.forw   3D_Plasmid_244.forw   3D_32 
tcatttcattcgccttttcc 60 40 catttcgatgccagatttga 60 40   
3D_Plasmid_241.rev   3D_Plasmid_240.forw   3D_33 
attagggatgctgcaaatgg 60 45 caggaaacactgcttgtgga 60 50   
3D_Plasmid_231.rev   3D_Plasmid_079.rev   3D_34 
atcgtgaccccagcattaga 60 50 tcacatctatgcattgacactca 59 39   
3D_Plasmid_155.rev   3D_Plasmid_159.forw   3D_35 
gaacgaaatactgaaccccaag 60 45 tctgacggcttattcggagt 60 50   
3D_Plasmid_095.forw   3D_Plasmid_096.rev   3D_36 
tggcattactcacctttttgg 60 42 atcggttggtttctgctttt 59 40   





59 30   
3D_Plasmid_199.rev   3D_Plasmid_065.forw   3D_38 
tgtgtaaatgagaaactgccaa
a 
60 35 tatgcgtgcgatttcatcat 60 40   
3D_Plasmid_225.forw   3D_Plasmid_076.forw   3D_39 
cgccatcgataaacgattca 62 45 aaggatcatgcttaagaataga
caga 
59 35   
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3D_Plasmid_225.forw   3D_Plasmid_066b.rev   3D_40 
cgccatcgataaacgattca 62 45 cctactatttccaatatcaatcaa
tca 
59 30   
3D_Plasmid_209.forw   3D_Plasmid_208.rev   3D_41 
caagcaaccgaaagaaaaca 59 40 gcgggtttacctttttctgg 61 50   
3D_Plasmid_209.forw   3D_Plasmid_205.rev   3D_42 
caagcaaccgaaagaaaaca 59 40 aaatgtctatgctatacggtgca
a 
60 38   
 
Master table B: Primers used in gap PCR 











3D_Plasmid_041.forw   3D_Plasmid_043.rev   3D_43 
tgcgaataatttgcttctgttg 60 36 gcaaaccacccaatgaactc 60 50   
3D_Plasmid_054.forw   3D_Plasmid_055.rev   3D_44 
ccagaagttgaggcgaagtg 61 55 tcaactaagccactcctttttg 56 41   
3D_Plasmid_270.forw   3D_Plasmid_269b.rev    3D_45 
gaaatagtacagatgtcgtaa
tga 
51 33 tgccacttaaacccaaccat 45 60   
3D_Plasmid_161.forw   3D_Plasmid_162.rev    3D_46 
gctataaacccaaatgaactg
g 
58 41 gcggtatccaggagttcatt 59 50   
3D_Plasmid_108b.for
w 
  3D_Plasmid_109b.rev    3D_47 
tcaagtggacattcattaagct
g 
60 39 ccacctgtaccagtcaattcaa 60 46   
3D_Plasmid_209b.for
w 
  3D_Plasmid_208.rev    3D_48 
gcaaagaaatacagccgaca 59 45 gcgggtttacctttttctgg 61 50   




gcaaagaaatacagccgaca 59 45 aaatgtctatgctatacggtgcaa 60 38   
3D_Plasmid_199.forw   3D_Plasmid_114.forw    3D_50 
tcatttcattcgccttttcc 60 40 cctgttgttccttggcgtat 60 55   
3D_Plasmid_187.forw   3D_Plasmid_188.rev    3D_51 
gcggcaaaagcttatcaaag 60 45 gcggtaaaatatactgatgtaaa
tgg 
59 35   
3D_Plasmid_187.forw   3D_Plasmid_274.rev    3D_52 
gcggcaaaagcttatcaaag 60 45 tgttacgatctccccaccat 60 50   
3D_Plasmid_079b.rev   3D_Plasmid_231.rev    3D_53 
taaatgagctgccgaaaagc 60 45 atcgtgaccccagcattaga 60 50   
3D_Plasmid_153.forw   3D_Plasmid_108.forw    3D_54 
tgccatatctactccccctct 60 53 ctacacaactccgcaaatcg 59 50   
3D_Plasmid_147.forw   3D_Plasmid_109.rev    3D_55 
gctcgaatagcagggaacg 61 58 tggtgccattacacataaaagg 60 41   
3D_Plasmid_147.forw   3D_Plasmid_270.forw    3D_56 
gctcgaatagcagggaacg 61 58 gaaatagtacagatgtcgtaatg
a 
51 33   
3D_Plasmid_108.forw   3D_Plasmid_270.forw    3D_57 
ctacacaactccgcaaatcg 59 50 gaaatagtacagatgtcgtaatg
a 
51 33   
3D_Plasmid_232.rev   3D_Plasmid_079b.rev    3D_58 
cttttgctggcagacagtga 60 50 taaatgagctgccgaaaagc 60 45   
3D_Plasmid_204.rev   3D_Plasmid_079b.rev    3D_59 
ggcgatattcttggagcatt 59 45 taaatgagctgccgaaaagc 60 45   
3D_Plasmid_204.rev   3D_Plasmid_209b.forw   3D_60 
ggcgatattcttggagcatt 59 45 gcaaagaaatacagccgac
a 
59 45   
3D_Plasmid_161b.for
w 
  3D_Plasmid_162b.rev    3D_61 
tggcaagctctaggattacctt 59 45 caactggaatgccttgcttt 60 45   
3D_Plasmid_160.forw   3D_Plasmid_160b.rev   3D_62 
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tcatcttcccaaggctctgt 60 50 tgaattacacgagggcaaaa 59 40   
3D_Plasmid_160.forw   3D_Plasmid_162b.rev   3D_63 
tcatcttcccaaggctctgt 60 50 caactggaatgccttgcttt 60 45   
3D_Plasmid_161b.for
w 
  3D_Plasmid_162b.rev   3D_64 
tggcaagctctaggattacctt 59 45 caactggaatgccttgcttt 60 45   
3D_Plasmid_161.forw   3D_Plasmid_162.rev   3D_65 
gctataaacccaaatgaactg
g 
58 41 gcggtatccaggagttcatt 59 50   
2C_Plasmid_229.forw   3D_Plasmid_160b.rev   3D_66 
tcccgaatgaacaacctacc 60 50 tgaattacacgagggcaaaa 59 40   
3D_Plasmid_161b.for
w 
      
tggcaagctctaggattacctt 59 45     
3D_Plasmid_160.forw       
tcatcttcccaaggctctgt 60 50     
3D_Plasmid_160b.rev       
tgaattacacgagggcaaaa 59 40     
 
 
 
 
 
